



Decide with Confidence

Compact Report

Report viewed

23 Feb 2015

Identification & Summary

A1 PHARMACEUTICALS PLC

Risk Evaluation

D&B Rating					2A 1
D&B Risk Indicator	1	2	3	4	-
D&B Failure Score					93
D&B Delinquency Score					95
Days Beyond Terms					15
D&B Maximum Credit					£1,701,000

Legal Events

Number of Court Judgments	0
Value of all Court Judgments	0
Number of Mortgages and Charges	5

Associations

Parent Company	No
Number of Principals	6

Financial Summary

Latest Accounts Date	30 Apr 2014
Tangible Net Worth	£6,855,308
Turnover	£51,372,002

Identification

Main Trading Address	Unit 20/21 RAINHAM ESSEX RM13 9BP UNITED KINGDOM
Telephone Number	01708-528900
Fax Number	01708 528928
D-U-N-S® Number	77-117-8241
Registered Number	2690345
Web Address	www.a1plc.co.uk
Registered Address	Unit 20 & 21 Easter Ind, Pk Ferry Lane South, Rainham, RM13 9BP UNITED KINGDOM
Line of Business (SIC)	PHARMACEUTICAL GOODS WHOLESALE (5122)

D&B Risk Assessment

D&B Rating	2A 1
Financial Strength	2A (based on tangible net worth) £6,855,308
Risk Indicator	1 Represents a minimum risk of business failure.

D&B Maximum Credit £1,701,000

Recommended credit exposure at any given time.

The D&B Maximum Credit is calculated using the D&B Failure Score, business size and primary industry sector.

D&B Failure Score 93 out of 100



D&B analytics have shown that businesses with this score have a very low probability of failure. 93% of UK businesses are classified in a higher risk category.

Incidence of failure 0.21% (21 per 10,000)

D&B Delinquency Score 95 out of 100



D&B analytics have shown that 5% of UK businesses have a lower risk of paying significantly late.

Incidence of delinquency 2.82% (282 per 10,000)

- The incidence of failure above shows the percentage of businesses with this Failure Score that have been subject to an insolvency event or gone out of business with outstanding debt.
- The incidence of delinquency above shows the percentage of businesses with this Delinquency Score that have paid late based on payment information reported to D&B.

The Scores and Ratings included in this report are designed as a tool to help credit professionals make their own credit related decisions, and should be used as part of a balanced and complete assessment relying on the knowledge and expertise of the reader, and where appropriate on other information sources.

The Score and Rating models are developed using statistical analysis in order to generate a prediction of future events. D&B monitors the performance of thousands of businesses for at least 12 months in order to identify characteristics common to specific business events. These characteristics are weighted by significance to form rules within our models that identify other businesses with similar characteristics and provide a Score and Rating.

Please note: (1) like all forward looking predictions, our Scores and Ratings are not a statement of what will happen, but an indication of what is more likely to happen based on previous experience; and (2) use of the term "insolvency event" in this report means (i) if a business has convened a meeting of its creditors, made a voluntary arrangement or proposal for any other composition scheme or arrangement with (or assignment for the benefit of) its creditors, (ii) if a business is unable to pay its debts, (iii) if a trustee receiver, administrative receiver or similar officer is appointed in respect of all or any material part of the business or its assets; (iv) if a meeting is convened for the purpose of considering a resolution, or other steps are taken for the winding up of the business (otherwise than for the purpose of an amalgamation or reconstruction) or for the making of an administration order or other appointment of an administrator in respect of the business, or any such order or appointment is made or effective resolution is passed to wind up the business.

Whilst D&B uses extensive procedures to maintain the quality of the information we hold, we cannot guarantee that it is always accurate, complete or up to date, and this may affect the Scores and Ratings we publish.

Public Notice Information

Public Notice information is added to the D&B Database and, if present, will appear in this section. This section was last updated from public sources on 23 Feb 2015.

Judgments

Judgments Registered During The Last 12 Months: 0

Mortgages and Charges

Number of registered charges: 5

Number of satisfied charges: 4

A petition for the winding-up of the above named company was presented on 17.02.2009 by De Fa Med G B R. On the 25.03.2009 the petition was dismissed. Pet No. 10753/2009.

Legal Filing Summary

Registered Number	2690345
Accounting Reference Date	3004
Latest Annual Return Date	21 Feb 2014
Latest Accounts Filed	30 Apr 2014

All public notice information has been obtained in good faith from the appropriate public sources.

Current Principals

Carmen Lewis:

Position	Managing Director
Date Appointed	26 Jun 1998
Position	Director
Date Appointed	24 Feb 1993
Position	Company Secretary
Date Appointed	24 Feb 1993

Gary Stephen Lewis:

Position	Director
Date Appointed	24 Feb 1993

Legal Structure

Legal Form	Public company
Date Started	1988
Business started by	"A1 Pharmaceuticals", trading as a partnership.
Date of Registration	24 Feb 1992
Registered Number	2690345
Registered office	Unit 20 & 21 Easter Ind, Pk Ferry Lane South, Rainham, RM13 9BP
Summary Issued Capital	13,570 divided into 50,000 Ordinary shares of 0.25 each, 10 Ordinary B shares of 1 each, 10 Ordinary C shares of 1 each, 10 Ordinary D shares of 1 each, 1,000 Othershares of 1 each,

Operations

Operating as	SIC Code	NACE Code	UK SIC Code
PHARMACEUTICAL GOODS WHOLESALERS	5122	-	-

Pharmaceutical suppliers and wholesalers

Other Operating Details

Employees 25

Financial Summary

	Fiscal Non consolidated GBP 30 Apr 2014	Fiscal Non consolidated GBP 30 Apr 2013	Fiscal Non consolidated GBP 30 Apr 2012
Sales Turnover	51,372,002	52,012,498	46,432,209
Profit / (Loss) Before Taxes	3,661,051	3,245,466	1,379,471
Tangible Net Worth	6,855,308	6,673,391	4,179,613
Net Current Assets (Liabilities)	6,527,090	6,300,051	4,074,509